






**A.**TyrCre;BrafCA;Perk<sup>+/−</sup>/TyrCre;BrafCA;Perk<sup>+/−</sup>**SI SCORE****Genotype**

Antibody	TyrCre;BrafCA; Perk <sup>+/−</sup>	TyrCre;BrafCA; Perk <sup>+/−</sup> + LY-4
CD31	+++	+
p-H3	++	+
Ki67	++	+
p-eIF2 $\alpha$	++	+
TUNEL	+	+++
CHOP	+++	+

**B.****C.****D.****E.****S3 Fig. Related to Figure 4.**

**A)** H&E and IHC analysis of Braf<sup>V600ECA/+</sup>/Perk<sup>+/-</sup> skin +/- LY-4, scale bars, 50  $\mu$ m. **B)** H&E of pancreas from control or LY-4 treated mice. **C)** LY-4 does not inhibit MAPK. **D)** Blood glucose levels +/- LY4; ; p-values analyzed by two-tailed Student t test. **E)** Survival curve of TyrCre; BrafCA/+ mice post LY-4 treatment.